"10.1371_journal.pone.0145403","plos one","2015-12-22T00:00:00Z","Francesco Mainini; David S Larsen; Gill A Webster; Sarah L Young; Michael R Eccles","Department of Pathology, University of Otago, Dunedin, New Zealand; Department of Chemistry, University of Otago, Dunedin, New Zealand; Innate Immunotherapeutics Ltd, 4B Walls Rd, Penrose, Auckland, New Zealand; Maurice Wilkins Centre for Molecular Biodiscovery, 3A Symonds Street, Auckland, New Zealand","Conceived and designed the experiments: FM DSL SLY MRE. Performed the experiments: FM. Analyzed the data: FM DSL SLY. Contributed reagents/materials/analysis tools: DSL GAW. Wrote the paper: FM DSL GAW MRE.","One of the authors [GAW] is the Chief Scientific Officer and holds shares in Innate Immunotherapeutics Limited, which supplied the MIS416 in order to carry out this study. This author [GAW] received salary from this organization. GAW, MRE and FM have submitted a patent relating to MIS416 (Compositions and methods for the delivery of agents that inhibit gene expression, application number 2014904383). GAW is also an inventor on another two patents relating to MIS416 (Anti infective agents and uses thereof, patent number 8709448; Compositions and methods for treatment of multiple sclerosis, patent number 8389479). Innate Immunotherapeutics has a product in development related to MIS416. None of the authors hold consultancies with Innate Immunotherapeutics, or any other consultancies relating to MIS416. No other authors declare competing interests. This commercial affiliation does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.","2015","12","Francesco Mainini","FM",5,TRUE,4,1,3,4,TRUE,TRUE,FALSE,0,NA,FALSE
